Variability of parvovirus B19 to inactivation by liquid heating in plasma products

Vox Sanguinis

Volumn 92, Issue 2, 2007, Pages 121-124

  Hattori, S ^a   Yunoki, M ^a,b   Tsujikawa, M ^a   Urayama, T ^a,b   Tachibana, Y ^a   Yamamoto, I ^a   Yamamoto, S ^a   Ikuta, K ^b  

^a Benesis Corporation   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Heat sensitivity; Parvovirus B19; Plasma products; Viral inactivation; Viral safety

Indexed keywords

ANTITHROMBIN; HAPTOGLOBIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MESSENGER RNA;

ANIMAL CELL; ARTICLE; CELL ASSAY; CONTROLLED STUDY; HEAT SENSITIVITY; HEAT TREATMENT; HEATING; HUMAN; HUMAN CELL; INFECTION; NONHUMAN; PARVOVIRUS; PLASMA; PRIORITY JOURNAL; TEMPERATURE DEPENDENCE; VIRUS INHIBITION;

ANIMALS; ANTICOAGULANTS; ANTITHROMBINS; BLOOD COMPONENT TRANSFUSION; DRUG CONTAMINATION; HAPTOGLOBINS; HEATING; HUMANS; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; PARVOVIRUS, PORCINE; SWINE; VIRUS INACTIVATION;

EID: 33846938064     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2006.00879.x     Document Type: Article

References (16)

1. The European Agency for the Evaluation of Medicinal Products/Committee for Proprietary Medical Products (CPMP) Biotechnology Working Party, Ad-Hoc Working Group on Blood Products: Workshop on Viral Safety of Plasma-Derived Medicinal Products with Particular Focus on Non-Enveloped Viruses. CPMP/BWP/BPWG/4080/00. 2001 http://www.emea.eu.int/index/indexh1.htm
2. The European Agency for the Evaluation of Medicinal Products/Committee for Proprietary Medical Products (CPMP) Biotechnology Working Party, Ad-Hoc Working Group on Blood Products: Guideline on Assessing the Risk for Virus Transmission - New Chapter 6 of the Note for Guidance on Plasma-derived Medicinal Products (CPMP/BWP/269/95). CPMP/BWP/5180/03. 2004 http://www.emea.eu.int/index/indexh1.htm
3. Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare: Guideline on the look-back review of blood products. Ref. No. 0310011 (10th March 2005). Tokyo, Japan, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare. [in Japanese]
4. Blümel J, Schmidt I, Willkommen H, Löwer J: Inactivation of parvovirus B19 during pasteurization of human serum albumin. Transfusion 2002; 42:1011-1018
5. Yunoki M, Tsujikawa M, Urayama T, Sasaki Y, Morita M, Tanaka H, Hattori S, Takechi K, Ikuta K: Heat sensitivity of human parvovirus B19 [published erratum appears in Vox Sang 2003; 85:67-68]. Vox Sang 2003; 84:164-169
6. Yunoki M, Urayama T, Tsujikawa M, Sasaki Y, Abe S, Takechi K, Ikuta K: Inactivation of parvovirus B19 by liquid heating incorporated in the manufacturing process of human intravenous immunoglobulin preparations. Br J Haematol 2005; 128:401-404
7. Kärber J: Beitrag zur kollectiven Behandlung pharmakologische Reihenversuche. Arch Exp Path Pharmak 1931; 162:480-483
8. Shade RO, Blundell MC, Cotmore SF, Tattersall P, Astell CR: Nucleotide sequence and genome organization of human parvovirus B19 isolated from the serum of a child during aplastic crisis. J Virol 1986; 58:921-936
9. Busby TF, Atha DH, Ingham KC: Thermal denaturation of anti-thrombin III. Stabilization by heparin and lyotropic anions. J Biol Chem 1981; 256:12140-12147
10. Umemori K, Okada Y, Mizusawa S, Yamaguchi K: Establishing the human parvovirus B19 infectivity assay using epithelial cells. Conference of the Japanese Society of Virology. Yokohama, Japan (2005). [in Japanese]
11. Prikhod'ko GG, Vasilyeva I, Reyes H, Wong S, Brown KE, Jameson T, Busby TE: Evaluation of a new LightCycler reverse transcription-polymerase chain reaction infectivity assay for detection of human parvovirus B19 in dry-heat inactivation studies. Transfusion 2005; 45:1011-1019
12. Prikhod'ko GG: Dry-heat sensitivity of human B19 and porcine parvovirus. Transfusion 2005; 45:1692-1693
13. Chapman MS, Rossmann MG: Structure, sequence, and function correlations among parvoviruses. Virology 1993; 194:491-508
14. Agbandje M, Kajigaya S, Mckenna R, Young NS, Rossmann MG: The structure of human parvovirus B19 at a 8Å resolution. Virol 1994; 203:106-115
15. Yunoki M, Urayama T, Nishida M, Tsujikawa M, Horii H, Nishimaki H, Uemura Y, Kagitani Y, Sato S, Kato T, Sekiguchi S: Virus validation study of a manufacturing process for Antithrombin-III. Iyakuhin Kenkyu 1999; 30:331-141 [in Japanese]
16. Mosquet B, Lacotte J, Le Querrec A, Petitjean J, Grollier G, Moulin M: Severe hematologic involvement in parvovirus B19 infection. Are antithrombin III injections the origin of the contamination? Therapie 1994; 49:471-472 [in French]